지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2015.1
- 수록면
- 661 - 669 (9page)
이용수
초록· 키워드
오류제보하기
Purpose Direct sequencing (DS) is the standard method for detection of epidermal growth factorreceptor (EGFR) gene mutation in non-small cell lung cancer (NSCLC); however, low detectionsensitivity is a problem. The aim of this study is to demonstrate higher detection rateof EGFR gene mutation with peptide nucleic acid (PNA) clamping compared with DS.
Materials and MethodsThis is a single arm, prospective study for patients with stage IIIB/IV or relapsed NSCLC.
Using tumor DNA from 138 patients, both DS and PNA clamping for EGFR gene in exon 18,19, 20, and 21 were performed. Discrepant results between the two methods were verifiedusing Cobas and a mutant enrichment based next generation sequencing (NGS). Patientswith activating mutations were treated with EGFR tyrosine kinase inhibitor (EGFR-TKI, gefitinib,or erlotinib) as first line treatment.
ResultsOf 138 paired test sets, 24 (17.4%) and 45 (32.6%) cases with activating mutations weredetected by DS and PNA clamping, respectively. The difference of detection rate betweenthe two methods was 15.2% (95% confidence interval, 8.7% to 17.8%; p < 0.001). Betweenthe two methods, 25 cases showed discrepant results (n=23, PNA+/DS–; n=2, PNA–/DS+).
Mutations were confirmed by Cobas or NGS in 22 of 23 PNA+/DS– cases. The responserates to EGFR-TKI were 72.2% in the PNA+/DS+ group and 85.0% in the PNA+/DS– group.
ConclusionPNA clamping showed a significantly higher detection rate of EGFR gene mutation comparedwith DS. Higher sensitivity of PNA clamping was not compromised by the loss of predictivepower of response to EGFR-TKI.
목차
등록된 정보가 없습니다.
참고문헌 (20)
참고문헌 신청
Takezawa K / 2012 / HER2 amplification : a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation / Cancer Discov 2:922~933
이재철 / 2013 / Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor / Cancer Research and Treatment 45(2):79~85
Dacic S / 2008 / EGFR assays in lung cancer / Adv Anat Pathol 15 : 241 ~ 247
Eisenhauer EA / 2009 / New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) / Eur J Cancer 45 : 228 ~ 247
Fukuoka M / 2011 / Biomarker analyses and final overall survival results from a phase III, randomized, openlabel, first-line study of gefitinib versus carboplatin/paclitaxel
이재철 / 2013 / Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor / Cancer Research and Treatment 45(2):79~85
Dacic S / 2008 / EGFR assays in lung cancer / Adv Anat Pathol 15 : 241 ~ 247
Eisenhauer EA / 2009 / New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) / Eur J Cancer 45 : 228 ~ 247
Fukuoka M / 2011 / Biomarker analyses and final overall survival results from a phase III, randomized, openlabel, first-line study of gefitinib versus carboplatin/paclitaxel
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey
Journal of Pathology and Translational Medicine
2015 .01
-
Analysis of an EGFR mutation by PNA clamping method in lung carcinoid tumors
고신대학교 의과대학 학술지
2015 .01
-
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
Cancer Research and Treatment
2020 .01
-
Clinical Validation of the Unparalleled Sensitivity of the Novel Allele-Discriminating Priming System Technology–Based EGFR Mutation Assay in Patients with Operable Non–Small Cell Lung Cancer
Cancer Research and Treatment
2024 .01
-
Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Peptide Nucleic Acid Clamping and Direct Sequencing in the Detection of Oncogenic Alterations in Lung Cancer: Systematic Review and Meta-Analysis
Yonsei Medical Journal
2018 .01
-
Provisional Guideline Recommendation for EGFR Gene Mutation Testing in Liquid Samples of Lung Cancer Patients: A Proposal by the Korean Cardiopulmonary Pathology Study Group
Journal of Pathology and Translational Medicine
2019 .01
-
Prevalence and Clinical Profile of EGFR Mutation In Non-Small-Cell Lung Carcinoma Patients in Southwest China
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned
Cancer Research and Treatment
2015 .01
-
Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01)
Journal of Pathology and Translational Medicine
2018 .01
-
Correlation of TTF-1 immunoexpression and EGFR mutation spectrum in non?small cell lung carcinoma
Journal of Pathology and Translational Medicine
2021 .01
-
Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases
Journal of Pathology and Translational Medicine
2016 .01
-
The application of transgenic mice with mutant EGFR in drug development and biological role
한국실험동물학회 학술발표대회 논문집
2022 .01
-
Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non-Small Cell Lung Cancer
Cancer Research and Treatment
2022 .01
-
Detection of Rare Mutations in EGFR-ARMS-PCR-Negative Lung Adenocarcinoma by Sanger Sequencing
Yonsei Medical Journal
2018 .01
-
Clinical Characteristics and Continued Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Administration in EGFR-Mutated Non-small Cell Lung Cancer with Skeletal Metastasis
Cancer Research and Treatment
2016 .01
-
Low-dose Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body Surface Area
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Anti-neoplastic cytotoxicity by complementary simultaneous selective “targeted” delivery for pulmonary adenocarcinoma: fludarabine-(5′-phosphoramidate)-[anti-IGF-1R] in dual-combination with dexamethasone-(C21-phosphoramidate)-[anti-EGFR]
Journal of Pharmaceutical Investigation
2019 .01
-
Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases
Journal of Pathology and Translational Medicine
2016 .01
-
EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer is Associated with a High Incidence of Brain Metastasis
Cancer Research and Treatment
2023 .04
이 논문의 저자 정보
최근 본 자료
댓글(0)
0